TABLE 1.
Demographics of lung transplant recipients in the Thymoglobulin, Campath, and daclizumab groups
| Thymoglobulin | Campath | Daclizumab | P value | |
|---|---|---|---|---|
| Number | 38 | 10 | 28 | |
| Average age (y) | 47 ± 13 (25–68) | 55 ± 11 (37–70) | 49 ± 14 (22–65) | NS |
| Sex (M/F) | 17/21 | 7/3 | 15/13 | NS |
| Underlying disease | NS | |||
| COPD | 12 (37%) | 2 (20%) | 8 (29%) | |
| CF | 8 (21%) | 5 (18%) | ||
| IPF | 5 (13%) | 4 (40%) | 8 (29%) | |
| A1A deficiency | 5 (13%) | 1 (3%) | ||
| Scleroderma/crest | 3 (8%) | 1 (10%) | 2 (7%) | |
| Sarcoidosis | 2 (5%) | |||
| PPH | 1 (3%) | 1 (3%) | ||
| Pulmonary fibrosis | 1 (3%) | |||
| EG | 1 (3%) | |||
| OB/Retx | 3 (30%) | 1 (3%) | ||
| Other | 2 (7%) | |||
| Type of transplantation | NS | |||
| Single | 17 (45%) | 5 (50%) | 12 (43%) | |
| Double | 20 (53%) | 4 (40%) | 15 (54%) | |
| Heart, double lung | 1 (10%) | |||
| Double lung + liver | 1 (2%) | |||
| Living lung donor lobar | ||||
| CMV (D+/R−) | 13/38 (34%) | 2/10 (20%) | 7/28 (25%) | NS |
| EBV (D+/R−) | 2/38 (5%) | 0/10 | 1/28 (3%) | NS |
| HLA mismatch | 4.5 ± 1.3 | 5.2 ± 0.8 | 5.2 ± 0.9 | NS |
| PRA > 10% | 1/38 (3%) | 1/10 (10%) | 2/28 (7%) | NS |
| Ischemia time (min) | 345 ± 101 | 354 ± 85 | 329 ± 82 | NS |
| Donor age (y) | 35 ± 15 (14–63) | 39 ± 16 (11–62) | 35 ± 15 | NS |
COPD, Chronic obstructive pulmonary disease; CF, cystic fibrosis; IPF, idiopathic pulmonary fibrosis; A1A deficiency, α1-antitrypsin deficiency; PPH, primary pulmonary hypertension; EG, eosinophilic granuloma; OB/Retx, obliterative bronchiolitis retransplantation; CMV, cytomegalovirus; EBV, Epstein-Barr virus; PRA, panel reactive antibody.